Department of Clinical Biochemistry, Hebrew University - Hadassah Medical Center, Jerusalem, Israel.
Neuropharmacology. 2010 Jun;58(7):972-80. doi: 10.1016/j.neuropharm.2009.12.017. Epub 2010 Jan 6.
Tissue type plasminogen activator (tPA) can induce neuronal apoptosis, disrupt the blood-brain barrier (BBB), and promote dilation of the cerebral vasculature. The timing, sequence and contributions of these and other deleterious effects of tPA and their contribution to post-ischemic brain damage after stroke, have not been fully elucidated. To dissociate the effects of tPA on BBB permeability, cerebral vasodilation and protease-dependent pathways, we developed several tPA mutants and PAI-1 derived peptides constructed by computerized homology modeling of tPA. Our data show that intravenous administration of human tPA to rats increases BBB permeability through a non-catalytic process that is associated with reversible neurotoxicity, brain damage, mortality and contributes significantly to its brief therapeutic window. Furthermore, our data show that inhibiting the effect of tPA on BBB function without affecting its catalytic activity, improves outcome and significantly extends its therapeutic window in mechanical as well as in thromboembolic models of stroke.
组织型纤溶酶原激活物(tPA)可诱导神经元凋亡、破坏血脑屏障(BBB)并促进脑血管扩张。tPA 及其对卒中后缺血性脑损伤的有害作用的这些和其他有害作用的时间、顺序和贡献尚未完全阐明。为了分离 tPA 对 BBB 通透性、脑血管扩张和蛋白酶依赖性途径的影响,我们通过 tPA 的计算机同源建模构建了几种 tPA 突变体和 PAI-1 衍生肽。我们的数据表明,静脉注射人 tPA 可增加大鼠 BBB 的通透性,这是一种非催化过程,与可逆神经毒性、脑损伤和死亡率相关,并显著与其短暂的治疗窗口有关。此外,我们的数据表明,抑制 tPA 对 BBB 功能的作用而不影响其催化活性,可以改善结果并显著延长其在机械和血栓栓塞性卒中模型中的治疗窗口。